Spots Global Cancer Trial Database for panitumumab
Every month we try and update this database with for panitumumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | NCT03992456 | Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Color... Stage III Recta... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta... Unresectable Co... Unresectable Co... Unresectable Re... | Panitumumab Quality-of-Life... Questionnaire A... Regorafenib Trifluridine an... | 18 Years - | Academic and Community Cancer Research United | |
| Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery | NCT03000374 | Rectal Cancer | Panitumumab 5Fluorouracil Oxaliplatin Leucovorin | 18 Years - 74 Years | Grupo Espanol Multidisciplinario del Cancer Digestivo | |
| Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC | NCT02593175 | Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-Negative... | Carboplatin Paclitaxel Panitumumab | 18 Years - | M.D. Anderson Cancer Center | |
| AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer | NCT03986541 | Colorectal Canc... | Immunohistochem... | 18 Years - | University of Leeds | |
| Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum | NCT00346099 | Rectal Cancer Neoplasm Metast... | Panitumumab wit... Panitumumab wit... | 18 Years - | NSABP Foundation Inc | |
| Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | NCT00655499 | Colorectal Canc... | Panitumumab Irinotecan hydr... Chromogenic in ... Fluorescence in... Gene expression... Laboratory biom... | 18 Years - 80 Years | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer | NCT00101907 | Lung Cancer Pancreatic Canc... Esophageal Canc... | AMG 706 Panitumumab Gemcitabine Cisplatin | 18 Years - | Amgen | |
| Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver | NCT02885753 | Colorectal Neop... | Oxaliplatin int... 5 FU bolus Folinic acid Oxaliplatin int... Panitumumab Bevacizumab 5 FU continuous Irinotecan | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC | NCT02593175 | Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-Negative... | Carboplatin Paclitaxel Panitumumab | 18 Years - | M.D. Anderson Cancer Center | |
| FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only | NCT01226719 | Colorectal Canc... | Panitumumab Oxaliplatin Irinotecan Leucovorin 5-Fluorouracil | 18 Years - | SCRI Development Innovations, LLC | |
| Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer | NCT01009983 | Breast Cancer Recurrent Breas... Stage IV Breast... | panitumumab paclitaxel carboplatin laboratory biom... immunohistochem... | 18 Years - | Wake Forest University Health Sciences | |
| Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation | NCT05198934 | Colorectal Canc... | Sotorasib Panitumumab Trifluridine an... Regorafenib | 18 Years - 100 Years | Amgen | |
| Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery | NCT00647530 | Colorectal Canc... | panitumumab capecitabine fluorouracil oxaliplatin | 18 Years - | University of Birmingham | |
| Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation | NCT05198934 | Colorectal Canc... | Sotorasib Panitumumab Trifluridine an... Regorafenib | 18 Years - 100 Years | Amgen | |
| Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN | NCT01305772 | Squamous Cell C... | Panitumumab Surgery Radiation Thera... | 18 Years - | Duke University | |
| Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | NCT01814501 | Mucinous Adenoc... Mucinous Adenoc... Recurrent Colon... Recurrent Recta... Signet Ring Ade... Signet Ring Ade... Stage IV Colon ... Stage IV Rectal... | panitumumab irinotecan hydr... fluorouracil leucovorin calc... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Panitumumab and Gemcitabine in Relapsed Ovarian Cancer | NCT01296035 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Panitumumab | 18 Years - | Women and Infants Hospital of Rhode Island | |
| Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases | NCT01508000 | Colorectal Canc... Liver Metastase... KRAS Wild Type ... | FOLFOX6 Bevacizumab Panitumumab Surgery | 18 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma | NCT00667420 | Esophageal Aden... Gastric Adenoca... | panitumumab, ep... | 18 Years - | Massachusetts General Hospital | |
| Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors | NCT00091806 | Tumors Oncology Solid Tumors | panitumumab (AB... Panitumumab | 18 Years - | Amgen | |
| Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer | NCT03263429 | Colorectal Canc... Metastatic Colo... RAS Wild Type C... Refractory Colo... | Glutaminase Inh... Panitumumab Irinotecan Hydr... Laboratory Biom... Pharmacological... Imaging with 11... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | NCT04185883 | Advanced Solid ... Kirsten Rat Sar... | Sotorasib Trametinib RMC-4630 Afatinib Pembrolizumab Panitumumab Carboplatin, pe... Atezolizumab Palbociclib MVASI® (bevaciz... TNO155 IV Chemotherapy... IV Chemotherapy... BI 1701963 AMG 404 Everolimus | 18 Years - 100 Years | Amgen | |
| New Individualized Therapy Trial for Metastatic Colorectal Cancer | NCT00867334 | Colorectal Neop... Colorectal Canc... | Imatinib mesyla... Standard-of-car... | 18 Years - | Inova Health Care Services | |
| Study of Panitumumab in the Treatment of Carcinoid Syndrome | NCT01172717 | Carcinoid Syndr... | Panitumumab | 18 Years - | Boston Medical Center | |
| Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer | NCT01791309 | Metastatic Colo... | combination pan... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer | NCT02399943 | Colorectal Canc... KRAS Wildtype NRAS Wildtype BRAF Wildtype | Trametinib Panitumumab | 18 Years - | University Health Network, Toronto | |
| I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations | NCT02818725 | Infiltrating Ur... KRAS Gene Mutat... | Chemotherapy Panitumumab | 18 Years - | UNICANCER | |
| CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater | NCT01202409 | Gastrointestina... | Panitumumab | 18 Years - | M.D. Anderson Cancer Center | |
| Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC | NCT04587128 | Metastatic Colo... | Panitumumab Cetuximab Irinotecan FOLFIRI Protoco... Bevacizumab | 18 Years - | University of Wisconsin, Madison | |
| Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino) | NCT02476045 | Metastatic Colo... | 5-fluorouracil,... panitumumab Oxaliplatin, 5-... | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy | NCT00364013 | Metastatic Colo... | Panitumumab FOLFOX regimen | 18 Years - | Amgen | |
| Chemoradiation and Panitumumab for Esophageal Cancer | NCT01077999 | Squamous Cell C... Adenocarcinoma Esophageal Canc... Gastro-esophage... | Carboplatin Paclitaxel panitumumab radiotherapy | 18 Years - 75 Years | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer | NCT00113763 | Colorectal Canc... Metastases | Best supportive... Panitumumab | 18 Years - | Amgen | |
| Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery | NCT03510208 | Malignant Brain... Malignant Gliom... | Near-Infrared F... Panitumumab Panitumumab-IRD... POINPOINT-IR900... | 18 Years - | Stanford University | |
| Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer | NCT02301962 | Cancer | Panitumumab | 18 Years - | Dr. Reddy's Laboratories Limited | |
| Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer | NCT05177796 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Breast Inflamma... Invasive Breast... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Triple-Negative... | Carboplatin Cyclophosphamid... Doxorubicin Paclitaxel Panitumumab Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer | NCT01776307 | Colorectal Canc... | BBI608 Panitumumab Capecitabine Cetuximab | 18 Years - | Sumitomo Pharma America, Inc. | |
| Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment | NCT01380262 | Colorectal Canc... Skin Toxicities | 18 Years - 85 Years | Maria Sklodowska-Curie National Research Institute of Oncology | ||
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | NCT05564377 | Advanced Malign... Anatomic Stage ... Anatomic Stage ... Locally Advance... Malignant Femal... Metastatic HER2... Metastatic Mali... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Unresectable HE... Unresectable Ma... | Alpelisib Binimetinib Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Fulvestrant Ipatasertib Leucovorin Magnetic Resona... Multigated Acqu... Mutation Carrie... Neratinib Malea... Nilotinib Hydro... Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Positron Emissi... Selumetinib Sul... Sotorasib | - | National Cancer Institute (NCI) | |
| Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer | NCT01668498 | Ras-wildtype Co... | Erythromycin Doxycycline | 18 Years - | AIO-Studien-gGmbH | |
| Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation | NCT04034173 | Treatment Relat... | Panitumumab Irinotecan Folinic acid 5-FU | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients | NCT06332079 | Colorectal Canc... | 166Holmium TARE Cetuximab Panitumumab 5-Fluorouracil Bevacizumab Capecitabine | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| Panitumumab and Gemcitabine in Relapsed Ovarian Cancer | NCT01296035 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Panitumumab | 18 Years - | Women and Infants Hospital of Rhode Island | |
| PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) | NCT00446446 | Cancer Carcinoma Head and Neck C... Metastases Metastatic Canc... Metastatic or R... Oncology Squamous Cell C... Tumors | Panitumumab | 18 Years - | Amgen | |
| Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies | NCT00984217 | Adenoma, Pleomo... Mixed Salivary ... Salivary Gland ... Syringoma, Chon... | Radiation Panitumumab | 18 Years - | University of Pittsburgh | |
| Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer | NCT00950820 | Colorectal Neop... | Oxaliplatin, Ca... Oxaliplatin, Ca... | 18 Years - | AIO-Studien-gGmbH | |
| Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer | NCT03186326 | Metastatic Colo... MSI | FOLFOX regimen FOLFIRI Protoco... Avelumab Panitumumab Cetuximab Bevacizumab Aflibercept | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cancer | NCT02643056 | Advanced Head a... | Panitumumab | 18 Years - | Southern Europe New Drug Organization | |
| Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | NCT00655499 | Colorectal Canc... | Panitumumab Irinotecan hydr... Chromogenic in ... Fluorescence in... Gene expression... Laboratory biom... | 18 Years - 80 Years | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer | NCT00894504 | Metastatic Brea... | Panitumumab Carboplatin Gemcitabine | 18 Years - | SCRI Development Innovations, LLC | |
| A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer | NCT01801904 | Metastatic Colo... | Panitumumab | 18 Years - | National Cancer Institute, Naples | |
| Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients | NCT06332079 | Colorectal Canc... | 166Holmium TARE Cetuximab Panitumumab 5-Fluorouracil Bevacizumab Capecitabine | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer | NCT01443377 | Rectal Cancer | Panitumumab | 18 Years - | National Center for Tumor Diseases, Heidelberg | |
| Botensilimab and Balstilimab Optimization in Colorectal Cancer | NCT06268015 | Colorectal Canc... | Botensilimab Balstilimab Oxaliplatin Leucovorin Fluorouracil Bevacizumab Panitumumab | 18 Years - | Duke University | |
| PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence | NCT04787341 | Colorectal Canc... | Regorafenib Panitumumab | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer | NCT01312857 | Metastatic Colo... | panitumumab Randomization t... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma | NCT05423197 | Head-and-neck S... | 89Zr-panitumuma... Panitumumab | 19 Years - | Stanford University | |
| Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients | NCT01384994 | Colorectal Canc... KRAS Wildtype After Resection... | Folic Acid 5-FU 5-FU Oxaliplatin Panitumumab Panitumumab Folic Acid 5-FU 5-FU Oxaliplatin | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy | NCT00332163 | Metastatic Colo... Skin Rash Skin Toxicities Colon Cancer Colorectal Canc... | Panitumumab Irinotecan FOLFIRI Pre-emptive Ski... Reactive Skin T... | 18 Years - 90 Years | Amgen | |
| Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery | NCT00647530 | Colorectal Canc... | panitumumab capecitabine fluorouracil oxaliplatin | 18 Years - | University of Birmingham | |
| SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial | NCT00418938 | Cancer Colon Cancer Colorectal Canc... Metastatic Canc... Rectal Cancer Metastatic Colo... | Panitumumab Bevacizumab Leucovorin Irinotecan 5-Fluorouracil | 18 Years - | Amgen | |
| Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer | NCT01412957 | Metastatic Colo... | Best Supportive... Panitumumab | 18 Years - | Amgen | |
| Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer | NCT05901545 | Head and Neck S... Recurrent Head ... | Panitumumab Indium In 111 P... Single Photon E... Computed Tomogr... Surgical Proced... Imaging agent Intraoperative ... Near Infrared I... Electrocardiogr... Biospecimen Col... | 19 Years - | Vanderbilt-Ingram Cancer Center | |
| Preoperative Panitumumab and Radiotherapy in Rectal Cancer | NCT00973193 | Rectal Cancer | panitumumab | 18 Years - | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | |
| Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations | NCT01206049 | Cholangiocarcin... | Gemcitabine Oxaliplatin Capecitabine Panitumumab Bevacizumab | 18 Years - | Vejle Hospital | |
| Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery | NCT00647530 | Colorectal Canc... | panitumumab capecitabine fluorouracil oxaliplatin | 18 Years - | University of Birmingham | |
| Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation | NCT06252649 | Metastatic Colo... | FOLFIRI Regimen Sotorasib Panitumumab Bevacizumab-aww... | 18 Years - | Amgen | |
| Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance) | NCT02089737 | Advanced or Rec... | Panitumumab | - | Takeda | |
| Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) | NCT05638295 | Advanced Malign... Metastatic Mali... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Panitumumab Sotorasib | 18 Years - | National Cancer Institute (NCI) | |
| PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors | NCT00819780 | Colon Cancer Colorectal Canc... Rectal Cancer Metastatic Colo... | Panitumumab Bevacizumab mFOLFOX6 | 18 Years - | Amgen | |
| Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE) | NCT03043950 | Metastatic Colo... RAS Wild-type | Panitumumab | 18 Years - | iOMEDICO AG | |
| Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal | NCT01843452 | Carcinoma of An... | RADIOTHERAPY PANITUMUMAB MITOMYCIN CAPECITABINE | 18 Years - | Centre Hospitalier Universitaire Vaudois | |
| Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery | NCT03384238 | Pancreatic Aden... | Fluorescence Im... Panitumumab Panitumumab-IRD... | 19 Years - | Stanford University | |
| A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck | NCT00756444 | Squamous Cell C... | Panitumumab Cisplatin 5FU | 18 Years - | Amgen | |
| Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer | NCT00550836 | Pancreatic Canc... | panitumumab erlotinib hydro... gemcitabine hyd... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC | NCT01042288 | Non-Small-Cell ... | Carboplatin Pemetrexed Panitumumab | 18 Years - | SCRI Development Innovations, LLC | |
| Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer | NCT00894504 | Metastatic Brea... | Panitumumab Carboplatin Gemcitabine | 18 Years - | SCRI Development Innovations, LLC | |
| Phase II Study of Irinotecan and Panitumumab | NCT00836277 | Esophageal Canc... | Panitumumab Irinotecan | 18 Years - | University of Pittsburgh | |
| Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies | NCT01634880 | Salivary Gland ... | Postoperative R... | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC | NCT02593175 | Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-Negative... | Carboplatin Paclitaxel Panitumumab | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
